Extended Data Fig. 6: BA.5(SR) RBD nanoparticle elicited potent immune responses.
a. Neutralization assay showing the antisera efficacy in the BALB/c mice vaccinated with one dose of 10 ug of BA.5, BA.5(S375), BA.5(F486) or BA.5(R493) RBD nanoparticles at day 28. n = 5 from 2 independent experiments. Data were presented as mean ± SEM. Adjusted p values were calculated using one-way ANOVA with Tukey′s multiple comparisons test (*p < 0.05, **p < 0.01, ****p < 0.0001). b. The uptake assay by flow showing RFP percentages of BMDMs, which were treated with RFP-BA.5, RFP-BA.5(S375), RFP-BA.5(F486) or RFP-BA.5(R493) RBD nanoparticles for four hours. n = 5 from 2 independent experiments. Data were presented as mean ± SEM. Adjusted p values were calculated using one-way ANOVA with Tukey′s multiple comparisons test (***p < 0.001, ns, not significant). c. Representative BIAcore plots of BA.5(SR) RBD monomer or nanoparticle bound to hACE2. The KD value shown as a mean of three independent experiments. d. Schematic of bivalent RBD nanoparticle construction and vaccination of K18-hACE2 mice. e. Viral RNA copies in the lungs of K18-ACE2 mice infected with BA.5 or Delta were determined by qRT-PCR and plotted as log10 copies per microgram total RNA. The dotted line indicates the limit of detection (LOD). n = 6 for each group. Data are represented as mean ± SD. Adjusted p values were calculated using one-way ANOVA with Tukey′s multiple comparisons test (∗∗∗∗p < 0.0001). f. Representative BIAcore plots of the antisera against BA.5 or XBB.1 RBD in the rabbit vaccinated with 2 does of indicated nanoparticles at day 14 post-dose 2. the indicated RBD nanoparticle immunizations bound to BA.5 RBD. g. Schematic of rhesus macaque vaccination.